Charytan DM, et al. - Given that metformin could have benefits on cardiovascular disease and the progression of kidney disease but is often withheld from people with diabetes and chronic kidney disease (CKD) due to the potential increased risk of lactic acidosis, researchers assessed metformin for safety and cardiovascular events in patients with type 2 diabetes and CKD. Study participants included 591 people who used metformin at baseline and 3,447 non-users. Findings suggested an independent association of metformin use with a reduced risk of all-cause mortality, cardiovascular death, the cardiovascular composite, and the kidney disease composite. Data reported that there were two cases of lactic acidosis. In patients with stage 3 CKD, metformin might be safer for use than previously considered and may lower the risk of death and cardiovascular events.